Aesthetic medicine:
Indications for: KYBELLA
To improve the appearance of moderate to severe convexity or fullness associated with submental fat.
Limitations of Use:
Not recommended for treating outside of the submental region.
Adult Dosage:
See full labeling. Should be administered by a healthcare professional. Give by SC inj into SC fat tissue in the submental area using an area-adjusted 2mg/cm2 dose. ≥18yrs: 0.2mL inj spaced 1cm apart. Max 50 injections (up to 10mL total) per single treatment; up to 6 single treatments given at least 1 month apart.
Children Dosage:
<18yrs: not established.
KYBELLA Contraindications:
Infection at inj sites.
KYBELLA Warnings/Precautions:
Screen for thyromegaly and cervical lymphadenopathy. Excessive skin laxity, prominent platysmal bands, or other conditions. Prior surgical or aesthetic treatment to submental area. Avoid injection into or near marginal mandibular branch of facial nerve, platysma, salivary glands, lymph nodes, muscles. Possible vascular injury due to inadvertent intravascular inj. Dysphagia or history of; avoid. Bleeding abnormalities. Inj site alopecia, ulceration, necrosis, and infection; withhold until resolved. Pregnancy. Nursing mothers.
KYBELLA Classification:
Cytolytic.
KYBELLA Interactions:
Excessive bleeding or bruising may occur with concomitant antiplatelets or anticoagulants; caution.
Adverse Reactions:
Inj site reactions (eg, edema/swelling, hematoma, pain, numbness, erythema, induration, paresthesia, nodule), headache, oropharyngeal pain, hypertension, nausea, dysphagia; paresis.
Drug Elimination:
Fecal.
Generic Drug Availability:
NO
How Supplied:
Single-patient use vials (2mL)—4
